您的位置: 首页 > 2017年5月 第48卷 第3期 > 文字全文
2023年7月 第38卷 第7期11
目录

EGFR基因突变与肿瘤标志物检测在肺部占位病变鉴别诊断中的价值研究

Research of EGFR gene mutations and tumor markers expression in lung placeholder lesions for differential diagnosis

来源期刊: 广州医药 | 1-6 发布时间:2021-12-01 收稿时间:2025/11/13 17:11:45 阅读量:18
作者:
关键词:
肺恶性肿瘤EGFR基因基因突变肿瘤标志物吸烟指数
Pulmonary malignant tumorEGFR geneGene mutationTumor markersSmoking index
DOI:
10.3969/j.issn.1000-8535.2017.03.001
收稿时间:
2017-02-14 
修订日期:
 
接收日期:
 
引用总数:
0  
目的 研究EGFR基因突变与系列肿瘤标志物在160例原发性肺癌患者及51例肺部良性占位病变患者中的表达状况,为肺部占位病变的诊断、鉴别诊断和治疗提供参考依据。方法 160例肺癌患者取新鲜病理组织标本,采用扩增阻滞突变系统荧光PCR(ARMS-PCR)技术检测EGER基因突变;160例肺癌患者和51例良性占位病变患者取外周静脉血用化学发光法检测系列肿瘤标志物,用χ2检验统计分析数据。结果 160例肺癌病例中,EGFR基因野生型比率为47.56%(78/164),EGFR基因突变型比率为52.44%(86/164),突变型中21L858R点突变占23.17%(38/164),19Del缺失突变占22.56%(37/164)。肺癌组中系列肿瘤标志物较良性占位组具显著高表达,P<0.01。差异有统计学意义。结论 肺癌致病与EGFR基因突变、肿瘤标志物高表达有显著正相关,通过肿瘤标志物和EGFR基因突变检测,结合影像学检查,将有助于肺部占位病变诊断和鉴别诊断,并为治疗手段选择提供参考依据。
Objective To research EGFR gene mutation and series of tumor markers expression in 160 patients with primary lung cancer and 51 patients with lung benign placeholder lesions, provide some references for the diagnosis, differential diagnosis and treatment in lung placeholder lesions. Methods We took fresh pathological tissue specimens from 160 cases of patients with lung cancer, Then used ARMS PCR technique to detect EGER gene mutations. We took the peripheral venous blood in 160 patients with lung cancer and 51 patients with lung benign placeholder lesions, with chemiluminescence method to detect series of tumor markers,and used thechi-square test to statistic and analysis data. Results In 160 cases of lung cancer patients,The EGFR gene wild type rate was 47.56%(78/164).The EGFR gene mutation type rate was 52.44%(86/164).In EGFR gene mutation type,The proportion of 21L858R mutation was 23.17%(38/164),19del mutation was 22.56%(37/164). Series of tumor markers had significantly higher expression in lung cancer group than in benign placeholder lesions group. P<0.01.The difference was statistically significant. Conclusion Lung cancer pathogenesis and EGFR gene mutations, tumor markers high expression was significantly positive correlation. Through a series of tumor markers and EGFR mutation testing, combined with imaging examination, it will contribute to the diagnosis and differential diagnosis in lung placeholder lesions, and provide the basis for treatment.
1、 郑名华,孙国栋,张郧樊,等.肿瘤标志物在肺癌诊疗中的研究进展[J]. 中国医学创新,2016,13(4):145-148. 郑名华,孙国栋,张郧樊,等.肿瘤标志物在肺癌诊疗中的研究进展[J]. 中国医学创新,2016,13(4):145-148.
2、 颜瑾,周琪卉,宁雅静,等.53例CT引导下经皮肺穿剌活检临床分析[J]. 临床肺科杂志,2016,21(10):1814-1816. 颜瑾,周琪卉,宁雅静,等.53例CT引导下经皮肺穿剌活检临床分析[J]. 临床肺科杂志,2016,21(10):1814-1816.
3、 PAN H,LIU R,LI S. Effects of lootinib on advanced non-small cell lung cancer with different EGFR phenotypes[J]. Cell Biochem Biophys,2014,70(1):553-558. PAN H,LIU R,LI S. Effects of lootinib on advanced non-small cell lung cancer with different EGFR phenotypes[J]. Cell Biochem Biophys,2014,70(1):553-558.
4、 YASUDA H,KOBAYSHI S,COSTA D B,et al. EGFR exon 20 insertion mutations in non-small-cell lung Cancer Preclinical data and clinical caplications[J]. Lancer Oncol,2012,13(1):e 23-31. YASUDA H,KOBAYSHI S,COSTA D B,et al. EGFR exon 20 insertion mutations in non-small-cell lung Cancer Preclinical data and clinical caplications[J]. Lancer Oncol,2012,13(1):e 23-31.
5、 TENRESSEN J A,BIGHAM A W, O' CONNOR T D,et al. Evolution and functional impact of rare coding Variation from deep sequencing of human exons[J]. Science,2012,337(6090):64-69. TENRESSEN J A,BIGHAM A W, O' CONNOR T D,et al. Evolution and functional impact of rare coding Variation from deep sequencing of human exons[J]. Science,2012,337(6090):64-69.
6、 SHAMA S V,BELL D W,SELTLEMAN J,et al. Epidermal growth factor receptor mutations in lung cancer[J]. Nat Rev Cancer,2007,7(3):69-81. SHAMA S V,BELL D W,SELTLEMAN J,et al. Epidermal growth factor receptor mutations in lung cancer[J]. Nat Rev Cancer,2007,7(3):69-81.
7、 郑军,谢贵元,李姣,等.非小细胞肺癌EGFR基因突变的临床意义研究[J]. 中国肿瘤临床,2014,41(14):904-907. 郑军,谢贵元,李姣,等.非小细胞肺癌EGFR基因突变的临床意义研究[J]. 中国肿瘤临床,2014,41(14):904-907.
8、 邱田,凌云,山灵,等.非小细胞肺癌患者表皮生长因子受体Kras基因突变检测及与临床病理特征的相关性[J]. 中国肿瘤临床与康复,2015,22(6):678-680. 邱田,凌云,山灵,等.非小细胞肺癌患者表皮生长因子受体Kras基因突变检测及与临床病理特征的相关性[J]. 中国肿瘤临床与康复,2015,22(6):678-680.
9、 赵静,赵金银,赵肖,等.ARMS技术联合Taqman 探针检测100例非小细胞肺癌EGFR基因突变[J]. 中国肺癌杂志,2013,16(1):25-32. 赵静,赵金银,赵肖,等.ARMS技术联合Taqman 探针检测100例非小细胞肺癌EGFR基因突变[J]. 中国肺癌杂志,2013,16(1):25-32.
10、 张静,梁智勇,曾喧,等.应用蝎形探针扩增阻滞突变系统检测非小细胞肺癌表皮生长因子受体基因突变与病理改变的关系[J]. 中华病理学杂志,2008,37(5):294-299. 张静,梁智勇,曾喧,等.应用蝎形探针扩增阻滞突变系统检测非小细胞肺癌表皮生长因子受体基因突变与病理改变的关系[J]. 中华病理学杂志,2008,37(5):294-299.
11、 周春燕,冯作化,药立波,等.医学分子生物学[M]. 2版.北京:人民卫生出版社,2014:232-234. 周春燕,冯作化,药立波,等.医学分子生物学[M]. 2版.北京:人民卫生出版社,2014:232-234.
12、 王冠军,赫捷.肿瘤学概论[M]. 1版.北京:人民卫生出版社,2013:200-207. 王冠军,赫捷.肿瘤学概论[M]. 1版.北京:人民卫生出版社,2013:200-207.
13、 段国辰,郭涛.非小细胞肺癌EGFR基因突变的研究进展[J]. 河北医药,2015,37(23): 3637-3639. 段国辰,郭涛.非小细胞肺癌EGFR基因突变的研究进展[J]. 河北医药,2015,37(23): 3637-3639.
14、 杨彦辉,邓波,王如文,等.应用ROC曲线评价PET/CT联合肿瘤标志物对肺癌的诊断效能[J]. 肿瘤学杂志,2016,22(2):110-115. 杨彦辉,邓波,王如文,等.应用ROC曲线评价PET/CT联合肿瘤标志物对肺癌的诊断效能[J]. 肿瘤学杂志,2016,22(2):110-115.
15、 CHEN W,ZHENG R,ZENG H,et al. Annal report on status of cancer in China[J]. Chin J cancer Res,2015,27(1):2-12. CHEN W,ZHENG R,ZENG H,et al. Annal report on status of cancer in China[J]. Chin J cancer Res,2015,27(1):2-12.
下一篇
出版者信息








《广州医药》公众号
目录